RU2016133980A - Композиции и способы для лечения заболеваний глаз - Google Patents
Композиции и способы для лечения заболеваний глаз Download PDFInfo
- Publication number
- RU2016133980A RU2016133980A RU2016133980A RU2016133980A RU2016133980A RU 2016133980 A RU2016133980 A RU 2016133980A RU 2016133980 A RU2016133980 A RU 2016133980A RU 2016133980 A RU2016133980 A RU 2016133980A RU 2016133980 A RU2016133980 A RU 2016133980A
- Authority
- RU
- Russia
- Prior art keywords
- age
- macular degeneration
- related macular
- eyes
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 29
- 208000030533 eye disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000002780 macular degeneration Diseases 0.000 claims 15
- 210000001508 eye Anatomy 0.000 claims 14
- 206010064930 age-related macular degeneration Diseases 0.000 claims 13
- 230000001575 pathological effect Effects 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 5
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 3
- 208000001344 Macular Edema Diseases 0.000 claims 3
- 206010025415 Macular oedema Diseases 0.000 claims 3
- 206010029113 Neovascularisation Diseases 0.000 claims 3
- 206010030113 Oedema Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 201000011190 diabetic macular edema Diseases 0.000 claims 3
- 201000010230 macular retinal edema Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000000849 parathyroid Effects 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- 206010033799 Paralysis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 210000005252 bulbus oculi Anatomy 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
- 208000033379 Chorioretinopathy Diseases 0.000 claims 1
- 208000020564 Eye injury Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010072138 Limbal stem cell deficiency Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033864 Paranoia Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 208000030555 Pygmy Diseases 0.000 claims 1
- 206010064714 Radiation retinopathy Diseases 0.000 claims 1
- 201000001949 Retinal Vasculitis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 206010043087 Tachyphylaxis Diseases 0.000 claims 1
- 206010053648 Vascular occlusion Diseases 0.000 claims 1
- 208000035307 Vitreous adhesions Diseases 0.000 claims 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 229960002833 aflibercept Drugs 0.000 claims 1
- 108010081667 aflibercept Proteins 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229940124570 cycloplegic agent Drugs 0.000 claims 1
- 230000003500 cycloplegic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000002647 laser therapy Methods 0.000 claims 1
- 229940076783 lucentis Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000003547 miosis Effects 0.000 claims 1
- 229960003407 pegaptanib Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 210000001957 retinal vein Anatomy 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930811P | 2014-01-23 | 2014-01-23 | |
| US61/930,811 | 2014-01-23 | ||
| PCT/US2015/012634 WO2015112831A1 (en) | 2014-01-23 | 2015-01-23 | Compositions and methods for treating ocular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016133980A true RU2016133980A (ru) | 2018-03-01 |
| RU2016133980A3 RU2016133980A3 (cg-RX-API-DMAC7.html) | 2018-10-26 |
Family
ID=53681968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016133980A RU2016133980A (ru) | 2014-01-23 | 2015-01-23 | Композиции и способы для лечения заболеваний глаз |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160339005A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3096617A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017503835A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160108554A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106132201A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015209264A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2937349A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL246791A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016009331A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016133980A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015112831A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007265460B2 (en) | 2006-06-26 | 2011-03-03 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
| NO2686520T3 (cg-RX-API-DMAC7.html) | 2011-06-06 | 2018-03-17 | ||
| MY204336A (en) | 2013-06-13 | 2024-08-23 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| CN114890943A (zh) | 2013-11-15 | 2022-08-12 | 阿克比治疗有限公司 | {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途 |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| UA123308C2 (uk) | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
| KR20180036580A (ko) | 2016-09-30 | 2018-04-09 | 주식회사 유스바이오팜 | 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물 |
| KR102252450B1 (ko) | 2017-02-09 | 2021-05-14 | 주식회사 아미코젠파마 | 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물 |
| JP2020508073A (ja) * | 2017-02-27 | 2020-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 網膜分離症の非ヒト動物モデル |
| AR111190A1 (es) * | 2017-03-22 | 2019-06-12 | Genentech Inc | Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados |
| WO2018202865A1 (en) * | 2017-05-05 | 2018-11-08 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
| WO2018232227A1 (en) * | 2017-06-15 | 2018-12-20 | The Trustees Of Columbia University In The City Of New York | Treatment of neurodegeneration via reprogramming metabolism by inhibiting phd |
| KR102050506B1 (ko) | 2017-06-20 | 2019-11-29 | 한국식품연구원 | 망막 질환 예방, 개선, 완화 또는 치료용 조성물 |
| JP2021523222A (ja) * | 2018-05-01 | 2021-09-02 | チビ，インコーポレイティド | 網膜への薬剤の持続送達のための点眼剤および方法 |
| MX2020011845A (es) | 2018-05-09 | 2021-01-15 | Akebia Therapeutics Inc | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. |
| JP2021533148A (ja) * | 2018-08-21 | 2021-12-02 | カリフォルニア インスティチュート オブ テクノロジー | 非漏出性または最小漏出性の脈絡膜または網膜脈管再生 |
| JP7280353B2 (ja) * | 2018-11-02 | 2023-05-23 | キョンブク ナショナル ユニバーシティ インダストリー－アカデミック コーオペレーション ファウンデーション | 黄斑変性予防又は治療用組成物 |
| EP3875092B1 (en) | 2018-11-02 | 2025-11-19 | Kyungpook National University Industry-Academic Cooperation Foundation | Composition for prevention or treatment of macular degeneration |
| WO2020098630A1 (en) * | 2018-11-14 | 2020-05-22 | Zhuhai Qiwei Bio-Technology Ltd. | Animal models, screening methods, and treatment methods for intraocular diseases or disorders |
| CN111308001B (zh) * | 2018-12-11 | 2024-11-29 | 上海市第一人民医院 | 人黄斑新生血管性疾病的代谢标记物及其应用 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| IL294873A (en) * | 2020-02-06 | 2022-09-01 | Perfuse Therapeutics Inc | Preparations for the treatment of eye diseases |
| EP4322985A4 (en) * | 2021-04-13 | 2025-02-19 | Unity Biotechnology, Inc. | METHODS OF TREATMENT OF RETINAL VASCULOPATHIES |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19650215A1 (de) * | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| WO2007101204A1 (en) * | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
| AU2007265460B2 (en) * | 2006-06-26 | 2011-03-03 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
| WO2009035534A2 (en) * | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| US8865748B2 (en) * | 2011-06-06 | 2014-10-21 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| CN114890943A (zh) * | 2013-11-15 | 2022-08-12 | 阿克比治疗有限公司 | {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途 |
-
2015
- 2015-01-23 JP JP2016548111A patent/JP2017503835A/ja active Pending
- 2015-01-23 RU RU2016133980A patent/RU2016133980A/ru not_active Application Discontinuation
- 2015-01-23 US US15/112,954 patent/US20160339005A1/en not_active Abandoned
- 2015-01-23 WO PCT/US2015/012634 patent/WO2015112831A1/en not_active Ceased
- 2015-01-23 CN CN201580015037.4A patent/CN106132201A/zh active Pending
- 2015-01-23 KR KR1020167022741A patent/KR20160108554A/ko not_active Withdrawn
- 2015-01-23 MX MX2016009331A patent/MX2016009331A/es unknown
- 2015-01-23 CA CA2937349A patent/CA2937349A1/en not_active Abandoned
- 2015-01-23 AU AU2015209264A patent/AU2015209264A1/en not_active Abandoned
- 2015-01-23 EP EP15740401.3A patent/EP3096617A4/en not_active Withdrawn
-
2016
- 2016-07-14 IL IL246791A patent/IL246791A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL246791A0 (en) | 2016-08-31 |
| KR20160108554A (ko) | 2016-09-19 |
| WO2015112831A8 (en) | 2016-09-01 |
| RU2016133980A3 (cg-RX-API-DMAC7.html) | 2018-10-26 |
| US20160339005A1 (en) | 2016-11-24 |
| MX2016009331A (es) | 2016-10-26 |
| EP3096617A4 (en) | 2017-09-13 |
| EP3096617A1 (en) | 2016-11-30 |
| CA2937349A1 (en) | 2015-07-30 |
| AU2015209264A1 (en) | 2016-08-04 |
| CN106132201A (zh) | 2016-11-16 |
| JP2017503835A (ja) | 2017-02-02 |
| WO2015112831A1 (en) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016133980A (ru) | Композиции и способы для лечения заболеваний глаз | |
| JP2017503835A5 (cg-RX-API-DMAC7.html) | ||
| RU2018128980A (ru) | Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза | |
| WO2019175727A1 (en) | Methods for treating ocular diseases | |
| JP2018508572A (ja) | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 | |
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| RU2749952C2 (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| RU2012134639A (ru) | Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза | |
| JP2013528563A5 (cg-RX-API-DMAC7.html) | ||
| WO2015060208A1 (ja) | 眼疾患の治療剤又は予防剤 | |
| US20060111388A1 (en) | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye | |
| TWI516266B (zh) | 用於治療青光眼及高眼壓症之腺苷ａ１促效劑 | |
| JP2013510852A5 (cg-RX-API-DMAC7.html) | ||
| JP2010514733A5 (cg-RX-API-DMAC7.html) | ||
| JP2020530475A5 (cg-RX-API-DMAC7.html) | ||
| WO2009023411A1 (en) | Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases | |
| JP2009524684A5 (cg-RX-API-DMAC7.html) | ||
| US20140302009A1 (en) | Medicinal Agent for Prevention or Treatment of Diseases Associated with Intraocular Neovascularization and/or Intraocular Vascular Hyperpermeability | |
| AU2018248425A1 (en) | Methods and compositions for treating retina-associated disease using CCR3-inhibitors | |
| Curran et al. | Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension | |
| JP2012505928A5 (cg-RX-API-DMAC7.html) | ||
| RU2016142578A (ru) | Производное алкинилиндазола и его применение | |
| Loukianou et al. | Sustained ocular hypertension following intravitreal injections of 0.5 ámg/0.05 áml ranibizumab | |
| RU2019114205A (ru) | Способы лечения глазного заболевания с применением ингибиторов csf-1r |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190218 |